DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

Information source: Philadelphia Veterans Affairs Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure; Congestive Heart Failure

Intervention: Isosorbide Dinitrate (Drug); Isosorbide Dinitrate + Hydralazine (Drug); Placebo (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Philadelphia Veterans Affairs Medical Center

Official(s) and/or principal investigator(s):
Julio A Chirinos, MD, PhD, Principal Investigator, Affiliation: Philadelphia VA Medical Center & University of Pennsylvania

Overall contact:
Julio A Chirinos, MD, PhD, Phone: 215-200-7779, Email: julio.chirinos@uphs.upenn.edu

Summary

The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.

Clinical Details

Official title: Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The change in late systolic load from wave reflections between baseline and after 24 weeks of randomized therapy

Secondary outcome:

The change in LV mass & collagen volume fraction measured by MRI; early mitral annular velocity, myocardial strain, 6-minute walk distance and NT-pro-BNP levels between baseline and after 24 weeks of randomized therapy

Change in quality of life

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Previous clinical diagnosis of heart failure with current New York Heart Association Class II-IV symptoms. 2. LV ejection fraction >50% on a clinically indicated echocardiogram or ventriculogram within 12 months prior to consent, in the absence of a change in cardiovascular status, as assessed by the principal investigators. 3. Must have had at least one of the following within the 12 months prior to consent 1. Hospitalization for decompensated HF 2. Acute treatment for HF with intravenous loop diuretic or hemofiltration. 3. Chronic treatment with a loop diuretic for control of HF symptoms. 4. Chronic diastolic dysfunction on echocardiography as evidenced by left atrial enlargement or at least stage II diastolic dysfunction. 5. Documentation of elevated NT-pro BNP levels or other natriuretic peptide marker (BNP, ANP) according to the laboratory and assay upper limit of normal in the previous year. 4. Stable medical therapy as defined by: 1. No addition or removal of ACE, ARB, beta-blockers, or calcium channel blockers (CCBs) for 30 days. 2. No change in dosage of ACE, ARBs, beta-blockers or CCBs of more than 100% for 30 days. 3. No change in diuretic dose for 10 days. Exclusion Criteria: 1. Rhythm other than sinus rhythm (i. e., atrial fibrillation). 2. Neuromuscular, orthopedic or other non-cardiac condition that prevents patient from walking in a hallway. 3. Non-cardiac condition limiting life expectancy to less than one year, per physician judgment. 4. Current or anticipated future need for nitrate therapy. 5. Valve disease (> mild aortic or mitral stenosis; > moderate aortic or mitral regurgitation). 6. Hypertrophic cardiomyopathy. 7. Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid). 8. Pericardial disease. 9. Primary pulmonary arteriopathy. 10. Have experienced a myocardial infarction or unstable angina, or have undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent. 11. Other clinically important causes of dyspnea such as morbid obesity or significant lung disease defined by clinical judgment or use of steroids or oxygen for lung disease. 12. Systolic blood pressure < 110 mmHg or > 180 mm Hg. 13. Diastolic blood pressure < 40 mmHg or > 100 mmHg. 14. Resting heart rate (HR) > 100 bpm. 15. A history of reduced ejection fraction (EF<50%). 16. Severe renal dysfunction (estimated GFR <30 ml/min/1. 73m2 by modified MDRD equation) GFR (mL/min/1. 73 m2) = 175 x (Scr)-1. 154 x (Age)-0. 203 x (0. 742 if female) x (1. 210 if African American) (conventional units), which would impede the safe administration of gadolinium for MRI studies contrast. 17. Hemoglobin <10 g/dL. 18. Patients with known severe liver disease (AST > 3x normal, alkaline phosphatase or bilirubin > 2x normal). 19. Patients with a clinically indicated stress test demonstrating significant ischemia within a year of enrollment which was not followed by percutaneous or surgical revascularization. 20. Listed for cardiac transplantation. 21. Allergy to isosorbide dinitrate or hydralazine. 22. Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardenafil or tadalafil, since the combination of nitrates and phosphodiesterase inhibitors can result in severe hypotension. 23. We will also exclude patients who are not suitable candidates for a cardiac MRI by virtue of having the following absolute or relative contraindications: (i) Central nervous system aneurysm clips; (ii) Implanted neural stimulators; (iii) Implanted cardiac pacemaker or defibrillator; (iv) Cochlear implant; (v) Ocular foreign body (e. g. metal shavings); (vi) Other implanted medical devices: (e. g. drug infusion ports); (vii) Insulin pump; (viii) Metal shrapnel or bullet; (ix) Claustrophobia; (x) Extreme obesity rendering the patient unable to fit into narrow-bore scanners; (xi) Unwillingness of the patient to undergo a cardiac MRI. All patients with metallic implants will be individually evaluated prior to MRI.

Locations and Contacts

Julio A Chirinos, MD, PhD, Phone: 215-200-7779, Email: julio.chirinos@uphs.upenn.edu

Philadelphia VA Medical Center, Philadelphia, Pennsylvania 19104, United States; Recruiting
Julio A Chirinos, MD, PhD, Phone: 215-823-5800, Ext: 6791, Email: julio.chirinos@uphs.upenn.edu
Julio A Chirinos, MD, PhD, Principal Investigator
Additional Information

Related publications:

Bhuiyan T, Maurer MS. Heart Failure with Preserved Ejection Fraction: Persistent Diagnosis, Therapeutic Enigma. Curr Cardiovasc Risk Rep. 2011 Oct;5(5):440-449.

Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 1: pressure and flow measurements and basic principles of wave conduction and reflection. Hypertension. 2010 Oct;56(4):555-62. doi: 10.1161/HYPERTENSIONAHA.110.157321. Epub 2010 Aug 23. Review.

Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 2: arterial pressure-flow and pressure-volume relations in humans. Hypertension. 2010 Oct;56(4):563-70. doi: 10.1161/HYPERTENSIONAHA.110.157339. Epub 2010 Aug 23.

Endo H, Shiraishi H, Yanagisawa M. Afterload reduction by hydralazine in children with a ventricular septal defect as determined by aortic input impedance. Cardiovasc Drugs Ther. 1994 Feb;8(1):161-6.

Greig LD, Leslie SJ, Gibb FW, Tan S, Newby DE, Webb DJ. Comparative effects of glyceryl trinitrate and amyl nitrite on pulse wave reflection and augmentation index. Br J Clin Pharmacol. 2005 Mar;59(3):265-70.

Lind L, Pettersson K, Johansson K. Analysis of endothelium-dependent vasodilation by use of the radial artery pulse wave obtained by applanation tonometry. Clin Physiol Funct Imaging. 2003 Jan;23(1):50-7.

Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician. 2003 Dec 15;68(12):2393-8. Review.

Downing GJ, Maulik D, Phillips C, Kadado TR. In vivo correlation of Doppler waveform analysis with arterial input impedance parameters. Ultrasound Med Biol. 1993;19(7):549-59.

Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial. Am J Cardiol. 2005 Oct 10;96(7B):37i-43i. Epub 2005 Aug 9. Review.

Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am J Respir Crit Care Med. 2003 May 1;167(9):1287.

Starting date: January 2012
Last updated: October 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017